U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H27Cl2N3O4
Molecular Weight 588.48
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-0893

SMILES

COC1=CC=C2C=C(C=CC2=C1)C3=CC(=NN3[C@@H](C)C4=CC=C(C=C4)C(=O)NCCC(O)=O)C5=CC(Cl)=CC(Cl)=C5

InChI

InChIKey=DNTVJEMGHBIUMW-IBGZPJMESA-N
InChI=1S/C32H27Cl2N3O4/c1-19(20-3-5-21(6-4-20)32(40)35-12-11-31(38)39)37-30(18-29(36-37)25-14-26(33)17-27(34)15-25)24-8-7-23-16-28(41-2)10-9-22(23)13-24/h3-10,13-19H,11-12H2,1-2H3,(H,35,40)(H,38,39)/t19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C32H27Cl2N3O4
Molecular Weight 588.48
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.diapedia.org/management/8104277114/glucagon-antagonism

MK-0893, developed by Merck, is a reversible and competitive antagonist with high binding affinity (IC(50) of 6.6 nM) and functional cAMP activity (IC(50) of 15.7 nM). MK-0893 reached Phase 2; 12 weeks of once daily oral dosing led to significant and dose-dependent reductions in fasting and post-prandial plasma glucose and in HbA1c, with similar low incidences of hypoglycaemia as a metformin cohort. Combinations with metformin and sitagliptin were also trialled, and risk for hypoglycaemia was assessed in healthy males which showed the drug caused lengthening of recovery times. However, plasma levels of LDL cholesterol and liver transaminases were increased in some studies, as was body weight and blood pressure, all of which were not evident pre-clinically, and MK-0893 was discontinued.

Originator

Curator's Comment: # Merck & Co

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.6 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral
Highest studied dose
unhealthy, ADULT
Health Status: unhealthy
Condition: type 2 diabetes mellitus
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: ALT increased, Weight increased...
AEs

AEs

AESignificanceDosePopulation
ALT increased
80 mg 1 times / day multiple, oral
Highest studied dose
unhealthy, ADULT
Health Status: unhealthy
Condition: type 2 diabetes mellitus
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
LDL cholesterol increased
80 mg 1 times / day multiple, oral
Highest studied dose
unhealthy, ADULT
Health Status: unhealthy
Condition: type 2 diabetes mellitus
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Weight increased
80 mg 1 times / day multiple, oral
Highest studied dose
unhealthy, ADULT
Health Status: unhealthy
Condition: type 2 diabetes mellitus
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.
2012 Jul 12
Patents

Sample Use Guides

Experimental: MK-0893 (40 mg) MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893. Experimental: MK-0893 (120 mg) MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
Route of Administration: Oral
MK-0893 suppressed glucagon induced cAMP production, with IC 50 of 563 nM in human primary hepatocytes.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:10:00 GMT 2023
Edited
by admin
on Fri Dec 15 16:10:00 GMT 2023
Record UNII
CCP2U6LWTP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MK-0893
Common Name English
MK0893
Common Name English
Code System Code Type Description
EVMPD
SUB194081
Created by admin on Fri Dec 15 16:10:00 GMT 2023 , Edited by admin on Fri Dec 15 16:10:00 GMT 2023
PRIMARY
DRUG BANK
DB12044
Created by admin on Fri Dec 15 16:10:00 GMT 2023 , Edited by admin on Fri Dec 15 16:10:00 GMT 2023
PRIMARY
FDA UNII
CCP2U6LWTP
Created by admin on Fri Dec 15 16:10:00 GMT 2023 , Edited by admin on Fri Dec 15 16:10:00 GMT 2023
PRIMARY
ChEMBL
CHEMBL1933349
Created by admin on Fri Dec 15 16:10:00 GMT 2023 , Edited by admin on Fri Dec 15 16:10:00 GMT 2023
PRIMARY
PUBCHEM
11570626
Created by admin on Fri Dec 15 16:10:00 GMT 2023 , Edited by admin on Fri Dec 15 16:10:00 GMT 2023
PRIMARY
SMS_ID
100000178371
Created by admin on Fri Dec 15 16:10:00 GMT 2023 , Edited by admin on Fri Dec 15 16:10:00 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
The addition of MK-0893 to either metformin or sitagliptin compared favorably with the classical metformin–sitagliptin combination. However, plasma levels of LDL cholesterol and liver transaminases were increased in some studies with MK-0893.
Related Record Type Details
ACTIVE MOIETY